VG-901

The FDA granted Rare Pediatric Disease Designation to ViGeneron's VG901, a gene therapy for retinitis pigmentosa caused by CNGA1 gene mutations, highlighting the urgent need for new treatments.

Recent developments in the treatment of retinal diseases include strategic collaborations, clinical trials, and studies highlighting advancements in personalized treatment and the increasing prevalence of retinopathy of prematurity.

Viridian Therapeutics' veligrotug met all primary and secondary endpoints in the THRIVE-2 Phase 3 trial for chronic thyroid eye disease (TED).

The FDA cleared United Therapeutics' UKidney for US trials, a gene-edited porcine kidney product intended for end-stage renal disease via xenotransplant.

ViGeneron GmbH has dosed the first patient in its Phase 1b clinical trial for VG901, a gene therapy aimed at treating retinitis pigmentosa caused by CNGA1 gene mutations. The trial evaluates the safety and efficacy of intravitreal VG901 injections, with results expected by the end of 2025.